Key facts
- Periotherapia’s last known valuation is $16.1M (Jan 2025).
- It has raised $14.9M; the latest was Later Stage VC ($4.8M) in Jan 2025.
- Notable investors include Mitsubishi UFJ Capital, Osaka University Venture Capital, Chushin Venture Capital, Chishima Land, Chishima Real Estate — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Periotherapia
- ·The full record, as it builds
Funding rounds
No funding rounds for Periotherapia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Periotherapia
Developer of medical treatments designed to tackle intractable diseases. The company's therapies construct a pipeline that makes use of disease-specific antibodies and contributes to early diagnosis and precision medicine using companion diagnostics, enabling health professionals to discover new drugs for breast cancers, heart failure, arteriosclerosis, renal failure and diabetic retinopathy.
- Sector
- Healthcare
- HQ
- Suita, Japan
- Founded
- 2017
- Employees
- 12
- Website
- periotherapia.co.jp/
- Ownership
- Privately Held (backing)
Periotherapia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Periotherapia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Periotherapia in its N-PORT filings yet. We sweep new filings monthly.